132 related articles for article (PubMed ID: 12467216)
21. Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.
Shimomura M; Yaoi T; Itoh K; Kato D; Terauchi K; Shimada J; Fushiki S
Int J Oncol; 2012 Apr; 40(4):995-1004. PubMed ID: 22179563
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
[TBL] [Abstract][Full Text] [Related]
23. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer.
Rosell R; Felip E
Semin Oncol; 2001 Aug; 28(4 Suppl 14):37-44. PubMed ID: 11605182
[TBL] [Abstract][Full Text] [Related]
24. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
[TBL] [Abstract][Full Text] [Related]
25. Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents.
Sackett DL; Giannakakou P; Poruchynsky M; Fojo A
Cancer Chemother Pharmacol; 1997; 40(3):228-32. PubMed ID: 9219506
[TBL] [Abstract][Full Text] [Related]
26. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
27. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
[TBL] [Abstract][Full Text] [Related]
28. ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.
Meng X; Wang G; Liu P; Hou J; Jin Y; Yu Y; Bai J; Chen F; Sun W; Fu S
Respirology; 2011 Nov; 16(8):1228-34. PubMed ID: 21883677
[TBL] [Abstract][Full Text] [Related]
29. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
[TBL] [Abstract][Full Text] [Related]
30. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).
Dumontet C; Duran GE; Steger KA; Beketic-Oreskovic L; Sikic BI
Cancer Res; 1996 Mar; 56(5):1091-7. PubMed ID: 8640766
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
Hari M; Loganzo F; Annable T; Tan X; Musto S; Morilla DB; Nettles JH; Snyder JP; Greenberger LM
Mol Cancer Ther; 2006 Feb; 5(2):270-8. PubMed ID: 16505100
[TBL] [Abstract][Full Text] [Related]
32. In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo.
Okugawa K; Kobayashi H; Hirakawa T; Sonoda T; Ogura T; Nakano H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):178-86. PubMed ID: 14655049
[TBL] [Abstract][Full Text] [Related]
33. Non-adherent culture induces paclitaxel resistance in H460 lung cancer cells via ERK-mediated up-regulation of βIVa-tubulin.
Atjanasuppat K; Lirdprapamongkol K; Jantaree P; Svasti J
Biochem Biophys Res Commun; 2015 Oct; 466(3):493-8. PubMed ID: 26375501
[TBL] [Abstract][Full Text] [Related]
34. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol.
Kavallaris M; Burkhart CA; Horwitz SB
Br J Cancer; 1999 Jun; 80(7):1020-5. PubMed ID: 10362110
[TBL] [Abstract][Full Text] [Related]
35. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.
Isonishi S; Saitou M; Saitou M; Yasuda M; Tanaka T
Oncol Rep; 2007 Jul; 18(1):195-201. PubMed ID: 17549368
[TBL] [Abstract][Full Text] [Related]
36. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
[TBL] [Abstract][Full Text] [Related]
37. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression.
Wehbe H; Kearney CM; Pinney KG
Anticancer Res; 2005; 25(6B):3865-70. PubMed ID: 16309172
[TBL] [Abstract][Full Text] [Related]
38. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation.
Martello LA; Verdier-Pinard P; Shen HJ; He L; Torres K; Orr GA; Horwitz SB
Cancer Res; 2003 Mar; 63(6):1207-13. PubMed ID: 12649178
[TBL] [Abstract][Full Text] [Related]
39. Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines.
Han EK; Gehrke L; Tahir SK; Credo RB; Cherian SP; Sham H; Rosenberg SH; Ng S
Eur J Cancer; 2000 Aug; 36(12):1565-71. PubMed ID: 10930805
[TBL] [Abstract][Full Text] [Related]
40. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
